Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actinium-225 radiolabelled OTSA 101 - National Institutes for Quantum and Radiological Science and Technology/OncoTherapy Science

Next Previous
X
Search
Drug Profile

Actinium-225 radiolabelled OTSA 101 - National Institutes for Quantum and Radiological Science and Technology/OncoTherapy Science

Alternative Names: 225 Ac labeled OTSA 101; Actinium-225-labeled OTSA 101; Anti-FZD10 antibody OTSA 101

Latest Information Update: 04 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes for Quantum and Radiological Science and Technology; OncoTherapy Science
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Synovial sarcoma

Most Recent Events

  • 27 Sep 2022 Pharmacodynamics and adverse events data from a preclinical studies in Synovial sarcomas released by National Institutes for Quantum and Radiological Science and Technology
  • 22 Dec 2021 OncoTherapy Science has patent protection for Actinium-225 labeled OTSA 101
  • 22 Dec 2021 Preclinical trials in Synovial sarcoma in Japan (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top